natgillin/translations-raw huggingface dataset:
It is recommended that those patients who have pre-existing cardiac abnormalities and/or are in advanced stages of cancer have electrocardiograms taken prior to and during the course of treatment. 
Priporočamo, da pri bolnikih z že obstoječimi srčnimi motnjami in/ali tistih, ki so v napredovalih stadijih maligne bolezni, EKG posnamete pred in po terapiji.
IntronA is indicated for the treatment of adult patients with chronic hepatitis C who have elevated transaminases without liver decompensation and who are positive for hepatitis C virus RNA (HCV-RNA) (see section 4.4). 
Zdravilo IntronA je indicirano za zdravljenje odraslih bolnikov s kroničnim hepatitisom C, ki imajo povečane vrednosti transaminaz brez dekompenzacije jeter in pozitiven izvid RNA virusa hepatitisa C (HCV-RNA) (glejte poglavje 4.4).
Increase in serum ALT/AST (SGPT/SGOT) levels have been noted as an abnormality in some non-hepatitis subjects and also in some patients with chronic hepatitis B coincident with clearance of viral DNAp. 
Povečanje serumske vrednosti ALT/AST (SGPT/SGOT) so opažali kot motnjo pri nekaterih osebah brez hepatitisa in tudi pri nekaterih bolnikih s kroničnim hepatitisom B skladno z očistkom virusne DNAp.
- The use of interferon alfa-2b in children and adolescents with existence of or history of severe psychiatric conditions is contraindicated (see section 4.3). 
- Uporaba interferona alfa-2b pri otrocih in mladostnikih, ki imajo ali so kdaj imeli hude psihiatrične motnje, je kontraindicirana (glejte poglavje 4.3).
If adverse events develop during the course of treatment with IntronA for any indication, modify the dose or discontinue therapy temporarily until the adverse events abate. 
Če se v teku zdravljenja z zdravilom IntronA za katerokoli od indikacij pojavijo neželeni učinki, prilagodite odmerjanje ali začasno ukinite zdravljenje, dokler neželeni učinki ne izzvenijo.
Children and adolescent population: Growth and development (chronic hepatitis C) During the course of interferon (standard and pegylated)/ribavirin combination therapy lasting up to 48 weeks in patients ages 3 through 17 years, weight loss and growth inhibition were common (see sections 4.8 and 5.1). 
Otroci in mladostniki: Rast in razvoj (kronični hepatitis C) Med kombinirano terapijo z interferonom (standardnim in pegiliranim) ter ribavirinom, ki je trajala do 48 tednov, sta bila pri bolnikih, starih od 3 do 17 let, hujšanje in zastoj rasti pogosta (glejte poglavji 4.8 in 5.1).
Detailed instructions for the subcutaneous use of the product are provided with the package leaflet (refer to “How to self inject IntronA”). 
Natančna navodila za subkutano uporabo zdravila so opisana v navodilu za uporabo (v poglavju "Kako si sami injicirate zdravilo IntronA").
Sustained virologic response rates for treatment groups treated for one year with IntronA alone or in combination with ribavirin (from two studies) are shown in Table 3. 
Deleži trajnega virološkega odziva po terapevtskih skupinah, zdravljenih eno leto z zdravilom IntronA v monoterapiji ali v kombinaciji z ribavirinom (iz dveh raziskav), so podani v preglednici 3.
Remove the needle from the vial and check for air bubbles in the syringe. 
Iglo izvlecite iz viale in preverite, ali so v brizgi morda zračni mehurčki.
The adverse reactions listed in Table 1 are based on experience from clinical trials and post-marketing. 
Neželeni učinki, podani v Preglednici 1, so povzeti iz kliničnih preskušanj in iz obdobja trženja.
Your doctor has determined the exact dosage for administration of IntronA according to your individual needs. 
Odmerek zdravila IntronA je zdravnik določil natančno glede na vaše individualne potrebe.
Cardiovascular (CVS) adverse events, particularly arrhythmia, appeared to be correlated mostly with pre-existing CVS disease and prior therapy with cardiotoxic agents (see section 4.4). 
Videti je bilo, da so kardiovaskularni (KVS) neželeni učinki, še posebej aritmija, odvisni predvsem od obstoječe KVS bolezni in predhodne terapije s kardiotoksičnimi snovmi (glejte poglavje 4.4).
A total of 118 patients were enrolled: 57 % male, 80 % Caucasian, and 78 % genotype 1,64 %  12 years of age. 
V študijo je bilo vključenih skupno 118 bolnikov; od tega je bilo 57 % moških, 80 % bolnikov bele rase, 78 % bolnikov z genotipom 1 in 64 % otrok, starih  12 let.
Children and adolescents should be monitored every 3 months for evidence of thyroid dysfunction (e.g. TSH). 
Otroke in mladostnike je treba spremljati na vsake 3 mesece in pri njih iskati morebitne znake motenj delovanja ščitnice (npr. spremembe vrednosti TSH).
Twenty (21 %) of 97 children had a > 15 percentile decrease in height percentile, of whom 10 of the 20 children had a > 30 percentile decrease in their height percentile from the start of treatment to the end of long-term follow-up (up to 5 years). 
Pri dvajsetih otrocih (21 %) od skupaj 97 otrok se je od začetka zdravljenja do konca dolgoročnega spremljanja bolnikov (do 5 let) percentil telesne višine zmanjšal za > 15 percentilov, pri 10 od teh 20 otrok pa se je percentil telesne višine zmanjšal za > 30 percentilov.
Adverse experiences including prolongation of coagulation markers and liver abnormalities Moderate to severe adverse experiences may require modification of the patient's dose regimen, or in some cases, termination of IntronA therapy. 
Neželeni učinki vključno s podaljšanimi parametri koagulacije in jetrnimi nepravilnostmi Pri zmernih do hudih neželenih učinkih je lahko potrebna prilagoditev režima odmerjanja, v nekaterih primerih pa tudi prekinitev terapije z zdravilom IntronA.
Patients predisposed to the development of autoimmune disorders may be at increased risk. 
Bolniki, ki so nagnjeni k nastanku avtoimunih bolezni, so lahko bolj ogroženi zaradi tega.
Prior to initiation of IntronA therapy for the treatment of chronic hepatitis C, evaluate serum thyroid-stimulating hormone (TSH) levels. 
Pred uvedbo terapije z zdravilom IntronA za zdravljenje kroničnega hepatitisa C določite serumsko koncentracijo tirotropnega hormona (TSH).
Treatment of high tumour burden follicular lymphoma as adjunct to appropriate combination induction chemotherapy such as a CHOP-like regimen. 
Zdravljenje folikularnega limfoma z veliko tumorsko obremenitvijo kot dodatno zdravljenje ob ustrezni kombinirani uvajalni kemoterapiji, kot je shema, podobna CHOP zdravljenju.
Measuring the dose of IntronA 
Merjenje odmerka zdravila IntronA
Females of childbearing potential must use an effective contraceptive during treatment and for 4 months after treatment has been concluded. 
Ženske v rodni dobi morajo učinkovito kontracepcijo uporabljati med zdravljenjem in še 4 mesece po zaključku zdravljenja.
HCV infected patients having a co-occurring substance use disorder (alcohol, cannabis, etc) are at an increased risk of developing psychiatric disorders or exacerbation of already existing psychiatric disorders when treated with alpha interferon. 
Pri bolnikih, okuženih s HCV, ki sočasno uživajo tudi opojne substance (alkohol, marihuano, itd.), je med zdravljenjem z interferonom alfa povečano tveganje za pojav psihiatričnih motenj ali za poslabšanje že obstoječih psihiatričnih motenj.
This syndrome is a granulomatous inflammatory disorder affecting the eyes, auditory system, meninges, and skin. 
To je granulomatozna vnetna bolezen, ki prizadene oči, slušni aparat, možganske ovojnice in kožo.
§, sepsis Hepatitis B reactivation in HCV/HBV co-infected patients 
§, sepsa reaktivacija hepatitisa B pri bolnikih, sočasno okuženih s HCV/HBV
The adverse reactions listed in Table 2 are based on experience from the two multicentre children and adolescent clinical trials. 
Neželeni učinki, ki so navedeni v Preglednici 2, so povzeti iz dveh multicentričnih kliničnih preskušanj pri otrocih in mladostnikih.
§, retinopathies (including macular oedema), retinal artery or vein obstruction 
§, retinopatija (vključno z edemom makule), zamašitev mrežnične arterije ali vene
In clinical trials conducted in the hepatitis C population, patients were treated with IntronA alone or in combination with ribavirin for one year. 
V kliničnih preskušanjih pri skupini bolnikov s hepatitisom C so bolnike eno leto zdravili z zdravilom IntronA samim ali v kombinaciji z ribavirinom.
Chronic hepatitis C in children and adolescent population Three clinical trials have been conducted in children and adolescents; two with standard interferon and ribavirin and one with pegylated interferon and ribavirin. 
Opravljena so bila tri klinična preskušanja pri otrocih in mladostnikih, dva s standardnim interferonom in ribavirinom in eno s pegiliranim interferonom in ribavirinom.
IntronA solution for injection or infusion may be injected directly after withdrawal of the appropriate doses from the vial with a sterile injection syringe. 
IntronA raztopino za injiciranje ali infundiranje lahko injicirate takoj, ko iz viale s sterilno injekcijsko brizgo posesate ustrezni odmerek.
If persistent or recurrent intolerance develops following adequate dose adjustment, or disease progresses, discontinue treatment with IntronA. 
Če se po ustrezni prilagoditvi odmerka pojavi trdovratna ali ponavljajoča intoleranca za zdravilo ali če bolezen napreduje, ukinite terapijo z zdravilom IntronA.
Clinically significant laboratory abnormalities, most frequently occurring at doses greater than 10 million IU daily, include reduction in granulocyte and white blood cell counts; decreases in haemoglobin level and platelet count; increases in alkaline phosphatase, LDH, serum creatinine and serum urea nitrogen levels. 
Med klinično pomembna odstopanja laboratorijskih vrednosti, ki se najpogosteje pojavijo pri odmerkih, večjih od 10 milijonov i.e. na dan, sodijo zmanjšanje števila granulocitov in levkocitov, zmanjšanje vrednosti hemoglobina in števila trombocitov, povečanje vrednosti alkalne fosfataze, LDH, serumskega kreatinina in dušika sečnine v serumu.
Discontinuation of IntronA therapy has not reversed thyroid dysfunction occurring during treatment (also see Thyroid supplemental monitoring specific for children and adolescents). 
IntronA motnje delovanja žleze ščitnice, ki so se pojavile med terapijo, niso minile (glejte tudi Dodatno spremljanje žleze ščitnice pri otrocih in mladostnikih).
In patients who are in the plateau phase (more than 50 % reduction of myeloma protein) following initial induction chemotherapy, interferon alfa-2b may be administered as monotherapy, subcutaneously, at a dose of 3 million IU/m2 three times a week (every other day). 
Pri bolnikih v fazi platoja (več kot 50 % zmanjšanje količine mielomskega proteina) po začetni uvajalni kemoterapiji lahko interferon alfa-2b aplicirate v obliki monoterapije, subkutano, v odmerku 3 milijone i.e./m2 trikrat na teden (vsak drugi dan).
Thyroid supplemental monitoring specific for children and adolescents Approximately 12 % of children treated with interferon alfa-2b and ribavirin combination therapy developed increase in thyroid stimulating hormone (TSH). 
Dodatno spremljanje žleze ščitnice pri otrocih in mladostnikih Pri približno 12 % otrok, zdravljenih s kombinirano terapijo z interferonom alfa-2b in ribavirinom, se je pojavilo povečanje vrednosti tirotropnega hormona (TSH).
- if you have a history of seizures (convulsions). 
- če ste imeli kdaj v preteklosti epileptične napade (konvulzije).
Periodic visual examinations during IntronA therapy are recommended particularly in patients with disorders that may be associated with retinopathy, such as diabetes mellitus or hypertension. 
Med zdravljenjem z zdravilom IntronA priporočamo redne preglede vida, še posebej pri bolnikih z boleznimi, ki so lahko povezane z retinopatijo, kot sta sladkorna bolezen ali hipertenzija.
Mutagenicity studies with interferon alfa-2b revealed no adverse events. 
Raziskave mutagenosti interferona alfa-2b niso pokazale nobenih neželenih učinkov.
IntronA must be used cautiously in patients with debilitating medical conditions, such as those with a history of pulmonary disease (e.g., chronic obstructive pulmonary disease) or diabetes mellitus prone to ketoacidosis. 
Zdravilo IntronA morate uporabljati previdno pri bolnikih z izčrpavajočimi bolezenskimi stanji, npr. pri tistih s pljučno boleznijo v anamnezi (npr. kronično obstruktivno pljučno boleznijo) ali sladkorno boleznijo z nagnjenostjo h ketoacidozi.
High tumour burden is defined as having at least one of the following: bulky tumour mass (> 7 cm), involvement of three or more nodal sites (each > 3 cm), systemic symptoms (weight loss > 10 %, pyrexia > 38°C for more than 8 days, or nocturnal sweats), splenomegaly beyond the umbilicus, major organ obstruction or compression syndrome, orbital or epidural involvement, serous effusion, or leukaemia. 
Velika tumorska obremenitev je opredeljena s tem, da ima bolnik najmanj enega od naslednjih znakov: obsežno tumorsko tvorbo (> 7 cm), prizadetost treh ali več skupin bezgavk (vsaka > 3 cm), sistemske simptome (zmanjšanje telesne mase > 10 %, zvišana telesna temperatura > 38 °C več kot 8 dni, nočno znojenje), splenomegalijo, ki sega pod popek, sindrom obstrukcije ali kompresije večjih organov, prizadetost orbite ali epiduralnih struktur, serozni izliv ali levkemijo.
IntronA is a sterile, stable, formulation of highly purified interferon alfa-2b produced by recombinant DNA techniques. 
Zdravilo IntronA je sterilna, stabilna oblika visokoprečiščenega interferona alfa-2b, izdelanega s tehnikami rekombinantne DNA.
High doses of other forms of interferons alpha and beta are known to produce doserelated anovulatory and abortifacient effects in rhesus monkeys. 
Tudi za velike odmerke drugih oblik interferonov alfa in beta je znano, da povzročijo od odmerka odvisne učinke v smislu izgube ovulacije ali splava pri opicah rhesus.
The combination of interferon alfa-2b and cytarabine (Ara-C) administered during the first 12 months of treatment has been demonstrated to significantly increase the rate of major cytogenetic responses and to significantly prolong the overall survival at three years when compared to interferon alfa-2b monotherapy. 
Raziskave so pokazale, da kombinacija interferona alfa-2b in citarabina (Ara-C), uporabljena v prvih 12 mesecih zdravljenja, bistveno poveča delež večjega citogenetskega odziva in bistveno podaljša skupno preživetje po 3 letih v primerjavi z monoterapijo z interferonom alfa-2b.
Treatment of adult patients with chronic hepatitis B associated with evidence of hepatitis B viral replication (presence of DNA of hepatitis B virus (HBV-DNA) and hepatitis B antigen (HBeAg), elevated alanine aminotransferase (ALT) and histologically proven active liver inflammation and/or fibrosis. 
Zdravljenje odraslih bolnikov s kroničnim hepatitisom B, ki imajo potrjeno replikacijo virusa hepatitisa B (prisotnost DNA virusa hepatitisa B (HBV-DNA) in antigen hepatitisa B (HBeAg)), povečano vrednost alanin-aminotransferaze (ALT) in histološko dokazano aktivno vnetje jeter in/ali fibrozo jeter.
Early intervention for re-emergence or development of psychiatric disorders and substance use is recommended. 
V primeru ponovnega pojava ali novega nastanka psihiatričnih motenj in uživanja opojnih substanc je priporočljivo zgodnje ukrepanje.
Adequate hydration must be maintained in patients undergoing IntronA therapy since hypotension related to fluid depletion has been seen in some patients. 
Pri bolnikih na terapiji z zdravilom IntronA morate vzdrževati ustrezno hidracijo, saj so pri nekaterih bolnikih opažali hipotenzijo zaradi izgube tekočine.
3 or ALT/AST rises to > 10 x upper limit of normal, discontinue interferon alfa-2b therapy. 
3 ali se vrednost ALT/AST zviša na > 10-kratno zgornjo mejo normale, terapijo z interferonom alfa-2b ukinite.
A total of 345 interferon alpha relapse patients were treated in two clinical trials with IntronA monotherapy or in combination with ribavirin. 
Skupaj 345 bolnikov z relapsom po zdravljenju z interferonom alfa je bilo zdravljenih v dveh kliničnih raziskavah z zdravilom IntronA, v monoterapiji ali v kombinaciji z ribavirinom.
IntronA has been classified as recombinant interferon alfa-2b. 
IntronA je opredeljen kot rekombinantni interferon alfa-2b.
All but one of the paediatric subjects remained sustained virologic responders during long-term follow-up after completion of treatment with interferon alfa-2b plus ribavirin. 
Pri vseh pediatričnih bolnikih razen pri enem se je trajni virološki odziv ohranil med dolgoročnim spremljanjem po zaključku zdravljenja z interferonom alfa-2b in ribavirinom.
Eligible patients for these trials had chronic hepatitis C confirmed by a positive HCV-RNA polymerase chain reaction assay (PCR) (> 100 copies/mL), a liver biopsy consistent with a histologic diagnosis of chronic hepatitis with no other cause for the chronic hepatitis, and abnormal serum ALT. 
Bolniki, primerni za vključitev v te raziskave, so imeli kronični hepatitis C, ki je bil potrjen s pozitivnim izvidom testa verižne reakcije s polimerazo za HCV-RNA (PCR) (> 100 kopij/ml), izvidom jetrne biopsije, ki je histološko potrdil diagnozo kroničnega hepatitisa brez drugega vzroka za kronični hepatitis, ter nenormalno serumsko vrednostjo ALT.
p value pegylated interferon alfa-2b (100 or c µg/week) + ribavirin 
vrednost p pegiliran interferon alfa-2b (100 ali c µg/ teden) + ribavirin mg)
Included are hairy cell leukaemia, chronic myelogenous leukaemia, multiple myeloma, follicular lymphoma, carcinoid tumour, and malignant melanoma. 
Te bolezni vključujejo dlakastocelično levkemijo, kronično mieloično levkemijo, multipli mielom, folikularni limfom, karcinoidni tumor in maligni melanom.
Among children and adolescents treated with IntronA in combination with ribavirin, suicidal ideation or attempts were reported more frequently compared to adult patients (2.4 % vs 1 %) during treatment and during the 6-month follow-up after treatment. 
Pri otrocih in mladostnikih, zdravljenih z zdravilom IntronA v kombinaciji z ribavirinom, so o samomorilnih mislih ali poskusu samomora poročali pogosteje kot pri odraslih (2,4 % v primerjavi z 1 %) med zdravljenjem in v času 6-mesečnega spremljanja bolnikov po zdravljenju.
Children and adolescents - Existence of, or history of severe psychiatric condition, particularly severe depression, suicidal ideation or suicide attempt. 
Otroci in mladostniki - Obstoječa huda duševna bolezen ali huda duševna bolezen v anamnezi, še posebej huda depresija, samomorilne misli ali poskus samomora.
a: p value based on Cochran-Mantel Haenszel Chi square test. b: p value based on chi-square test. c: subjects < 75 kg received 100 µg/week pegylated interferon alfa-2b and subjects ≥ 75 kg received 150 µg/week pegylated interferon alfa-2b. 
= milijonov mednarodnih enot; TIW = trikrat na teden a: vrednost p na podlagi Cochran-Mantel Haenszelovega hi-kvadrat testa b: vrednost p na podlagi testa hi-kvadrat c: Preiskovanci s telesno maso < 75 kg so prejemali pegilirani interferon alfa-2b v odmerku 100 µg/teden in preiskovanci s telesno maso ≥ 75 kg so prejemali pegilirani interferon alfa-2b v odmerku 150 µg/teden.
Pull back on the plunger slowly to draw the correct dose as prescribed by your doctor into the syringe (Diagram A). 
Počasi povlecite bat nazaj, da v brizgo izvlečete ustrezen odmerek zdravila, kot ga je predpisal zdravnik (slika A).
Children and adolescents 3 to 16 years of age with compensated chronic hepatitis C and detectable HCV-RNA (assessed by a central laboratory using a research-based RT-PCR assay) were enrolled in two multicentre trials and received IntronA 3 MIU/m2 3 times a week plus ribavirin 15 mg/kg per day for 1 year followed by 6 months follow-up after-treatment. 
Otroci in mladostniki, stari od 3 do 16 let, s kompenziranim kroničnim hepatitisom C in merljivimi količinami HCV RNA (kar je ocenil osrednji laboratorij z uporabo raziskovalnega testa RT-PCR), so bili vključeni v dve multicentrični preskušanji in so zdravilo IntronA prejemali v odmerku 3 mio i.e./m2 trikrat na teden skupaj z ribavirinom v odmerku 15 mg/kg na dan v obdobju enega leta, čemur je sledilo 6-mesečno spremljanje po zdravljenju.
10 million IU/mL 
10 milijonov i.e./ml
Administration of IntronA in combination with other chemotherapeutic agents (e.g., Ara-C, cyclophosphamide, doxorubicin, teniposide) may lead to increased risk of toxicity (severity and duration), which may be life-threatening or fatal as a result of the concomitantly administered medicinal product. 
Uporaba zdravila IntronA skupaj z drugimi kemoterapevtiki (npr. Ara-C, ciklofosfamidom, doksorubicinom, tenipozidom) lahko poveča tveganje toksičnosti (tako jakost kot trajanje), ki je lahko smrtno nevarna ali povzroči smrt zaradi sočasno danega zdravila.
Press the injection site with a small bandage or sterile gauze if necessary for several seconds. 
Po potrebi za nekaj sekund pritisnite na mesto injiciranja z majhno obvezo ali sterilno gazo.
Administration of IntronA in combination with other chemotherapeutic agents (e.g., Ara-C, cyclophosphamide, doxorubicin, teniposide) may lead to increased risk of toxicity (severity and duration) (see section 4.4). 
Uporaba zdravila IntronA skupaj z drugimi kemoterapevtiki (npr. Ara-C, ciklofosfamidom, doksorubicinom, tenipozidom) lahko poveča tveganje za toksičnost zdravila (tako jakost kot trajanje) (glejte poglavje 4.4).
As in adult patients, children and adolescents experienced other psychiatric adverse events (e.g., depression, emotional lability, and somnolence). 
Tako kot pri odraslih bolnikih so se tudi pri otrocih in mladostnikih pojavili drugi psihiatrični neželeni učinki (npr. depresija, čustvena labilnost in zaspanost).
Table 1 Adverse reactions reported during clinical trials or following the marketing use of IntronA alone or in combination with ribavirin 
Preglednica 1 Neželeni učinki, o katerih so poročali med kliničnimi preskušanji ali v obdobju trženja za zdravilo IntronA samo ali v kombinaciji z ribavirinom
IntronA is presented as a solution for injection or infusion. 
Zdravilo IntronA je na voljo kot raztopina za injiciranje ali infundiranje.
At the beginning of treatment with IntronA, you may experience a flu-like reaction, with fever, fatigue, headache, muscle ache, joint pain and chills/rigors. 
Na začetku zdravljenja z zdravilom IntronA boste lahko imeli gripi podobno reakcijo z zvišano telesno temperaturo, utrujenostjo, glavobolom, mišičnimi bolečinami, bolečinami v sklepih in mrzlico ali tresenjem.
Therapy may continue for as long as the patient responds to interferon alfa-2b treatment. 
Zdravljenje lahko nadaljujete vse dokler se bolnik odziva na interferon alfa-2b.
The population enrolled mainly consisted of children with mild to moderate hepatitis C. Due to the lack of data in children with severe progression of the disease, and the potential for undesirable effects, the benefit/risk of the combination of peginterferon alfa-2b with ribavirin needs to be carefully considered in this population (see peginterferon alfa-2b and ribavirin SPCs section 4.4). 
Populacija, vključena v preskušanje, je bila sestavljena predvsem iz otrok z blagim do zmernim hepatitisom C. Zaradi pomanjkanja podatkov pri otrocih z močno napredovalo boleznijo in zaradi nevarnosti za pojav neželenih učinkov je treba pri tej skupini bolnikov skrbno pretehtati razmerje med tveganji in koristmi zdravljenja s kombinacijo peginterferona alfa-2b in ribavirina (glejte SPC-ja za peginterferon alfa-2b in ribavirin, poglavje 4.4).
Other CNS effects including aggressive behaviour (sometimes directed against others such as homicidal ideation), bipolar disorders, mania, confusion and alterations of mental status have been observed with alpha interferons. 
Pri alfa interferonih so opažali tudi druge učinke na CŽS, vključno z agresivnim obnašanjem (ki je včasih usmerjeno proti drugim, kot je ideja o umoru), bipolarno motnjo, manijo, zmedenostjo in spremembami duševnega statusa.
Interferon alfa-2b has been shown to have abortifacient effects in Macaca mulatta (rhesus monkeys) at 90 and 180 times the recommended intramuscular or subcutaneous dose of 2 million IU/m2. 
Za interferon alfa-2b so študije pokazale, da povzroča splav pri opicah rhesus (Macaca mulatta), če ga prejemajo v odmerku, ki je 90 oz. 180-krat večji od priporočenega intramuskularnega ali subkutanega odmerka 2 milijona i.e./m2.